POSSIBILITIES OF THE ANALYSIS OF THE INDIVIDUAL ADRENOREACTIVITY OF THE BODY FOR EVALUATING THE THROMBOGENESIS RISK FACTORS
Abstract
The aim of the study was to determine the parameters of the aggregogram, allowing to take into account the risk of individual adrenoreactivity of the body in thrombogenesis. Methods. The study included aggregation curves, which were registered in 34 healthy volunteers when stimulating platelets in vitro with adrenaline at a concentration of 5 μM, which caused a maximum aggregation amplitude of 50 ± 5%. Registration of the aggregation process was carried out on Chrono-Log aggregometer (USA). Two types of aggregation patterns were analyzed: mono- and two-phase; the following parameters were automatically determined: Amplitude (maximum aggregation amplitude), Lag phase (delay of aggregation beginning), Slope (aggregation rate), and Area under curve (AUC). In addition, the values of the primary and secondary waves of two-phase curves were calculated. All volunteers in test in vitro produced normal adrenoreactivity. The monophase curve was characterized by interference of primary and secondary aggregation waves, high values of Slope and AUC. During registration of two-phase curve, two types of curves were detected that differed in rate from primary and secondary aggregation waves. At the first type of two-phase curve in comparison with the second type, high primary aggregation wave rate (Slope1), lower Lag phase delay and higher AUC values were detected. A distinctive feature of the second type of curve was the high rate of secondary aggregation wave (Slope2). Conclusion. The analysis of indicators, which characterized platelet aggregation curve allows to get additional information about individual adrenoreactivity of the body, which can contribute to the concretization of trombogenesis risk factors.
References
2. Peace A.J., Mangiacapra F. Bailleul E., et al. α2A-adrenergic receptor polymorphism potentiates platelet reactivity in patients with stable coronary artery disease carrying the cytochrome P450 2C19*2 genetic variant. Arterioscler Thromb Vasc Biol. 2014; 34(6):1314-1319.
3. Cattaneo M., Hayward C.P., Moffat K.A., et al. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH. J Thromb Haemost. 2009; 7(6):1029.
4. Paniccia R., Priora R. Liotta A.A., Abbate R. Platelet function tests: a comparative review. Vasc Health Risk Manag. 2015; 11:133-148.
5. Güngör Z.B., Ekmekçi H., Tüten A., et al. Is there any relationship between adipocytokines and angiogenesis factors to address endothelial dysfunction and platelet aggregation in untreated patients with preeclampsia? Arch Gynecol Obstet. 2017; 296 (3): 495-502.
6. Melanie McCabe White, Lisa K. Jennings. Platelet Protocols: Research and Clinical Laboratory Procedures: Academic Press; 1999; 116.
7. Jae-Lim Choi, Shuhua Li, Jin-Yeong Han. Platelet Function Tests: A Review of Progresses in Сlinical Application. Hindawi Publishing Corporation, BioMed Research International. 2014; (2014), Article ID 456569, 7 pages.
8. Tokuda H., Kuroyanagi G., Tsujimoto M., Enomoto Y., Matsushima-Nishiwaki R., Onuma T. et al. Release of phosphorylated hsp27 (hspb1) from platelets is accompanied with the acceleration of aggregation in diabetic patients. PLoS One. 2015;10(6): e0128977.
9. Christersson C., Lindahl B., Siegbahn A. The composition and daily variation of microparticles in whole blood in stable coronary artery disease. Scand J Clin Lab Invest. 2016; 76(1): 25-32.
10. Hines P.C., Gao X., White J.C., et al. A novel role of h2-calponin in regulating whole blood thrombosis and platelet adhesion during physiologic flow. Physiol Rep. 2014;2(12).pii: e12228.
